Statement Of Cash Flows [Abstract]

Hyloris Pharmaceuticals SA - Filing #5880972

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations
6,826,000 EUR
12,756,000 EUR
Interest paid, classified as operating activities
77,000 EUR
52,000 EUR
Cash flows from (used in) operating activities
6,903,000 EUR
12,808,000 EUR
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
29,000 EUR
298,000 EUR
Purchase of intangible assets, classified as investing activities
268,000 EUR
452,000 EUR
Interest received, classified as investing activities
556,000 EUR
638,000 EUR
Cash flows from (used in) investing activities
259,000 EUR
9,889,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from borrowings, classified as financing activities
139,000 EUR
51,000 EUR
Repayments of borrowings, classified as financing activities
40,000 EUR
- EUR
Payments of lease liabilities, classified as financing activities
267,000 EUR
170,000 EUR
Interest paid, classified as financing activities
- EUR
12,000 EUR
Cash flows from (used in) financing activities
168,000 EUR
131,000 EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
6,812,000 EUR
3,051,000 EUR
Cash and cash equivalents
23,594,000 EUR
30,406,000 EUR
33,457,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.